Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2006 by Peking University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Peking University
ClinicalTrials.gov Identifier:
NCT00378443
First received: September 19, 2006
Last updated: September 21, 2006
Last verified: September 2006
  Purpose

IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN. Both ACEi/ARB and steroid was found to be effective in slowing the rate of disease progression, but the use of steroid was restricted because of its side effects. However, there is no evidence from RCT on the question of whether combined use of steroid with ACEi/ARB can bring more benefit to IgAN patients than ACEi/ARB alone. We therefore undertook a randomized, multicenter study to investigate the efficacy and safety profile of combined use of ACEi/ARB plus steroid compared with ACEi/ARB alone in the treatment of patients with IgAN.


Condition Intervention
Glomerulonephritis, IGA
Drug: prednisone + Inhibace/Cozaar
Drug: Inhibace/Cozaar

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Peking University:

Primary Outcome Measures:
  • Serum creatinine
  • 24 hour urinary protein excretion

Secondary Outcome Measures:
  • Urinalysis
  • serum urea
  • serum albumin

Study Start Date: January 2006
Estimated Study Completion Date: June 2007
Detailed Description:

IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN. In the many studies on the treatment of IgAN, both ACEi/ARB and steroid was found to be effective in slowing the rate of disease progression, but the use of steroid was restricted because of its side effects, and ACEi/ARB was considered to be the first line therapy. However, there is no evidence from RCT on the question of whether combined use of steroid with ACEi/ARB can bring more benefit to IgAN patients than ACEi/ARB alone. We therefore undertook a randomized, multicenter study to investigate the efficacy and safety profile of combined use of ACEi/ARB plus steroid compared with ACEi/ARB alone in the treatment of patients with IgAN.

  Eligibility

Ages Eligible for Study:   16 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. underwent renal biopsy within 1 year before start fo trial;
  2. 24 hour urinary protein excretion ranged between 1 to 7 g/d;
  3. eGFR, evaluated by MDRD formula, should be higher than 30 ml/min

Exclusion Criteria:

  1. crescentic glomerulonephritis;
  2. steroid therapy subjected within 1 year before trial;
  3. malignant hypertension(DBP> 130 mmHg and/or SBP> 220mmHg), resistant to anti-hypertensive agents;
  4. urinary protein excretion decrease below 1 g/l after run-in period;
  5. Myocardial infarction or cerebrovascular accident in 6 months preceding the trial;
  6. renovascular disease;
  7. diabetes mellitus;
  8. Malignancy, severe liver disease, refractory infection;
  9. peptic ulcer in active disease phase;
  10. pregnancy;
  11. other contraindication to the use of ACEi/ ARB or corticosteroid;
  12. alcohol abuse or drug addiction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00378443

Sponsors and Collaborators
Peking University
Investigators
Principal Investigator: Hong Zhang, MD Renal Division, Peking University First Hospital
  More Information

No publications provided by Peking University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00378443     History of Changes
Other Study ID Numbers: [2006]022
Study First Received: September 19, 2006
Last Updated: September 21, 2006
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Glomerulonephritis
Glomerulonephritis, IGA
Autoimmune Diseases
Immune System Diseases
Kidney Diseases
Nephritis
Urologic Diseases
Cilazapril
Losartan
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Anti-Arrhythmia Agents
Antihypertensive Agents
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014